Registered Members Login:
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

4373 Pages (Click to Jump) V  « < 58 59 60 61 62 63 64 > »    
Reply to this topic

post Posted: Feb 18 2019, 04:19 PM
  Quote Post

Posts: 640
Thanks: 1553

Some coverage from Motley Fool

The Clinuvel share price has hit an all-time high and is up 188% in 12 months

The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price continued its strong run on Monday and climbed 7% to a new all-time high of $24.60.

This means that Clinuvel, a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders, has seen its share price rise a staggering 188% since this time last year.

Why is the Clinuvel share price on fire?
The main catalyst for this gain has been the impressive sales growth of its SCENESSE product over the last 12 months.

Clinuvel developed SCENESSE as a first-line pharmaceutical product aimed at treating patients with the rare genetic disorder erythropoietic protoporphyria (EPP).

The product has been a huge success and has significant growth opportunities ahead, notably in the United States where the US Food and Drug Administration has granted a Priority Review for SCENESSE on July 8.

This means that if it can satisfy the FDA’s requirements the drug could be on sale in the United States in the near future.

Is SCENESSE a good product?
It appears to be held in high esteem by physicians. According to the company, as of June 2018, 98.5% of the European EPP patients who had received treatment during the previous two years were continuing to receive SCENESSE in the third annual cycle.

Management believes this is significant as the company does not actively promote the drug treatment but enables clinical demand and purchase orders to occur as is.

It explained that this commercial approach reflects its belief in an open system where patients and physicians can decide together whether a treatment should be received and prescribed without the pharmaceutical company intervening.

Should you invest?
Whilst I’m a big fan of Clinuvel and its management team, I’m not a huge fan of its share price right now after this stellar run.

In light of this, I see far more value in healthcare sector peers Cochlear Limited (ASX: COH) and CSL Limited (ASX: CSL) than Clinuvel. But I would certainly add its shares to your watchlist just in case a buying opportunity presents itself further down the line.

Said 'Thanks' for this post: andymen  waz  
post Posted: Feb 18 2019, 04:17 PM
  Quote Post

Posts: 361
Thanks: 225

In Reply To: LevelHeaded2000's post @ Feb 18 2019, 03:25 PM

Solid volume for a Monday, hopefully a sign of things to come this week. I’m slightly suspicious (in a good way) that the volume traded is deliberate and in aid of getting into the ASX 200. Feasible? Perhaps, the timing seems more than coincidental.

On the other hand we kinda knew it was going to rise sooner or later leading up to July, admittedly I thought some of the rise was already baked in but since Sphene has Clinuvel at approx $35-42 with FDA onboard for EPP then we might see some unprecedented action in 2019.

And just to be a miser, I thought $23.80 was a poor finish😜🤣

Said 'Thanks' for this post: waz  Johnny H  
post Posted: Feb 18 2019, 03:25 PM
  Quote Post

Posts: 317
Thanks: 589

Wild trading day. 170k shares traded. one of the highest trading days ever. A sleeping dragon is waking.

Said 'Thanks' for this post: macgyver  johnnytech  
post Posted: Feb 18 2019, 02:59 PM
  Quote Post

Posts: 23
Thanks: 32

In Reply To: johnnytech's post @ Feb 18 2019, 02:15 PM

On IG Markets webpage it says ASX 300 shares are tradeable through their account.

post Posted: Feb 18 2019, 02:58 PM
  Quote Post

Posts: 358
Thanks: 603

In Reply To: johnnytech's post @ Feb 18 2019, 02:15 PM

The CFD pricing is pegged to CUV on the ASX
You are not buying the underlying are trading the price movement.

post Posted: Feb 18 2019, 02:19 PM
  Quote Post

Posts: 480
Thanks: 556

In Reply To: Johnny H's post @ Feb 18 2019, 11:08 AM

There are 4 types of market in Australia - DS just means data source. There are the 2 visible markets ASX Trade Match ™ and CHI-X (CXA) exchanges.
Then the 2 exchanges have hidden liquidity markets (ASX Centrepoint / CHI-X HL - you wont see that depth in visible).
Then the final type are Dark Pools run by Brokers (but they have very specific rules that are used to execute)
The DS just means ASX ™ lit price, CHIX (CXA) lit price or a mix of ASX and CHI-X lit price - also referred to as NBBO, National Best Bid Offer.

Said 'Thanks' for this post: investek  Johnny H  

post Posted: Feb 18 2019, 02:15 PM
  Quote Post

Posts: 369
Thanks: 670

In Reply To: xray's post @ Feb 18 2019, 12:51 PM

Is that a CUV thing or is it eligible with CLVLY too?

post Posted: Feb 18 2019, 01:25 PM
  Quote Post

Posts: 317
Thanks: 589

The rise in SP and more important the volume will help cement chance of getting into the ASX 200. I would put the chance we enter in March at 70%. And if not at that time, then 100% by June.

I am not sure what is driving the SP other than increased exposure and existing holders knowing the potential is still way higher so they aren't willing to sell at these low prices. Recently management has shown a more active role in communicating, conferencing, and shows willingness to start gearing up for new indications, so finally it looks like management is willing to execute (I think they have been and still are waiting for FDA approval before they do a full on marketing blitz of the company and product).

Whatever the cause of the SP rise it is being done at high volumes which is a good sign. In fact, the most likely reason for the rise in volume is people with more time to calculate the float-adjusted liquidity / market cap of all 500 companies already know whether it will enter in ASX200. So, this could be front-loaded demand for that eventuality in March.

Said 'Thanks' for this post: Verharven  waz  
post Posted: Feb 18 2019, 12:51 PM
  Quote Post

Posts: 358
Thanks: 603

In Reply To: Johnny H's post @ Feb 18 2019, 12:23 PM

You can trade Clinuvel as a CFD (contract for difference) on IG Markets.
I took 10,000 at around $12 and sold at $22
Margin was around 40% on that amount.
I think it is only 25% margin at or below 4000 shares.
As with any leveraged product, you can get your arse burnt big time if you are going in the wrong direction.

Said 'Thanks' for this post: macgyver  Johnny H  waz  johnnytech  
Johnny H
post Posted: Feb 18 2019, 12:23 PM
  Quote Post

Posts: 521
Thanks: 644

In Reply To: johnnytech's post @ Feb 18 2019, 11:52 AM

CLVLY is a non-marginable security, as are most OTC stocks.

Clinuvel until my bowels release for the last time.

4373 Pages (Click to Jump) V  « < 58 59 60 61 62 63 64 > » 

Back To Top Of Page
Reply to this topic

You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.